

PCT/EP99/04331  
Atty. Dkt. No. P67431US0

18. A medicament containing at least one serine protease inhibitor according to claim 15 and/or a nucleic acid coding for the serine protease inhibitor, optionally together with a pharmaceutical vehicle.
19. The medicament according to claim 18, containing from 0.01 to 1000 mg per kg of body weight of the serine protease inhibitor and/or the nucleic acid.
20. Use of the serine protease inhibitor according to claim 15 for preparing a medicament for the treatment of acute or chronic cervix inflammations, inflammations of Bartholin's glands and other vaginal regions, tonsillitis, pharyngitis and laryngitis, acute or chronic inflammatory processes accompanied by excessive formation of mucus and the resulting acute emergency situations, postoperative bleedings due to hyperfibrinolysis, and for the prophylaxis of lung emphysema formation in deficiencies of  $\alpha_1$ -proteinase inhibitor.
21. Use of the medicament according to claim 18 for the therapy of asthma, AIDS, pneumonia, tumor diseases and leukemia.
22. Use of the nucleic acid according to claim 17 for preparing a medicament for use in gene therapy for the curing and prophylaxis of acute or chronic cervix inflammations, inflammations of Bartholin's glands and other vaginal regions, tonsillitis, pharyngitis and laryngitis, acute or chronic inflammatory processes accompanied by excessive formation of mucus and the resulting acute emergency situations, postoperative bleedings due to hyperfibrinolysis, and for the prophylaxis of lung emphysema formation in deficiencies of  $\alpha_1$ -proteinase inhibitor.

PCT/EP99/04331  
Atty. Dkt. No. P67431US0

23. Antibodies or antibody fragments against epitopes of the compound according to claim 15.
24. Poly- or oligonucleotides which will hybridize to regions of the cDNA or corresponding RNA under stringent conditions and optionally prevent the expression of coding regions of the genes coding for the compound according to claim 15.
25. A diagnostic agent containing at least one compound according to claim 23.
26. A medicament containing at least one compound according to claim 23 in a therapeutically effective amount.
27. Use of the compound of claim 23 for preparing a medicament for the treatment of diseases involving too high an expression of the serine protease inhibitor or too high an activity of the regions coding for the serine protease inhibitor.
28. DNA coding for the compound of claim 15 and/or RNA involved in the transcription or translation of the compound.

---

REMARKS

The present claims are 15-28.

The present claims correspond to original claims 1-14, rewritten to eliminate multiple dependencies and to more clearly define the invention.